Harmonized Micronutrient Project

计划入组 146 人 · 首次发布于 2013 年 4 月 4 日

Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration

计划入组 5 人 · 首次发布于 2011 年 1 月 6 日

Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

计划入组 13 人 · 首次发布于 2009 年 12 月 16 日

Kalomin

Malonic acid

C₃H₄O₄

Palomid 529

C₂₄H₂₂O₆

Genomic Prediction, Inc.

United States

GENOMIC HEALTH, INC.

United States

International Atomic Energy Agency

Austria

Tangram Therapeutics Initiates First-in-Human Trial of TGM-312 for MASH Treatment

Tangram Therapeutics Advances Novel RNAi Therapy TGM-312 to Clinical Trials for MASH Treatment

Tangram's TGM-312 Advances to MASH Patient Cohorts in Phase 1/2 RESTORE-MASH Trial